A string of disappointing results for Merck KGaA’s bintrafusp alfa culminated in the termination of the German firm’s $4.2bn partnership with GlaxoSmithKline plc for the anticancer product at the end of September.
Bintrafusp alfa had been an important asset for both companies. GSK paid $360m upfront for a stake in the bifunctional...